Additionally, such CLEC14A targeting could be combined with immunotherapies which rely on infiltration of effector immune cells into the tumour mass, where functional and more ‘normal’ vasculature would likely be advantageous 109. This evidence concerns the gene CLEC14A and neoplasm.